Sodium-glucose Co-transporter 2 Inhibitors in Acute Heart Failure: A Review of the Available Evidence and Practical Guidance on Clinical Use

Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors were initially conceived as glucose-lowering agents. However, striking renal and cardiovascular benefits were observed in type 2 diabetes trials. This led to evaluate it in dedicated studies in chronic heart failure (HF) and chronic kidney disease, which also showed remarkable clinical results. Given this findings, and taking into account the multiple mechanisms of action, the use of SGLT2 inhibitors in acute heart failure seemed promising. Sotagliflozin was the first SGLT2 inhibitor to reduce heart failure hospitalizations within the acute setting in the SOLOIST-WHF trial. Only type 2 diabetes patients were included, with a preserved and reduced ejection fraction. In slightly less than half of the cohort, this medication was started when the diuretic therapy was transitioned from intravenous to oral, during the hospital admission. In the rest of the patients, sotagliflozin was started early after discharge. Empagliflozin proved to be safe, well-tolerated, increased diuresis, and reduced a combined clinical endpoint (worsening HF, rehospitalization for HF, or death at 60 days) when administered within the first 24 hours of an acute heart failure hospitalization in the EMPA-RESPONSE-AHF trial. More recently, empagliflozin showed a reduction in a composite primary endpoint of death, heart failure events, and quality of life compared to placebo in the EMPULSE trial. Empagliflozin was started after the initial stabilization phase, but while patients were still admitted and receiving intravenous loop diuretics. Less than half of the patients were diabetic and two-thirds had a left ventricular ejection fraction below 40%. Dapagliflozin is currently being tested in the DAPA ACT HF-TIMI 68 trial, which plans to enroll 2400 patients admitted with acute heart failure and reduced ejection fraction. We envision SGLT2 inhibitors as a useful tool in acute heart failure syndrome given the additive diuretic effect, and minimal impact on blood pressure, kidney function, and electrolytes. Its dosage schedule is simple and can help initiation and tolerance of other medical therapy. However, there is an increased risk of genital infections and euglycaemic ketoacidosis. Notwithstanding, once critically ill and fasting patients are excluded, early administration of SGLT2 inhibitors is safe. This review summarizes the development of SGLT2 inhibitors and the available evidence supporting their use during an acute heart failure admission. We also propose a practical guideline for in-hospital initiation and monitoring.

Sodium-glucose co-transporter 2 inhibitors: their role in heart failure management in emergency departments

“…Se ha observado un mayor riesgo de cetoacidosis, sin embargo, el riesgo absoluto adicional de esta complicación es bajo (0,3% por año) y se asocia a pacientes con sarcopenia o bajos índices de masa corporal, disminución brusca de la dosis de insulina tras su introducción, deshiwww.reue.org Llorens P. Rev Esp Urg Emerg. 2023;2:164-169 dratación o hipovolemia, ingesta alimentaria escasa y episodios recientes de cetoacidosis 5,8,20 . Los iSGLT2 tiene un efecto relativamente débil sobre la presión arterial (PA) sistólica, con una disminución de 3 a 5 mmHg aproximadamente.…”

“…Los iSGLT2 se asocian con un disminución leve del FG reversible y transitoria, que es secundaria a una vasoconstricción arteriolar aferente glomerular, lo que resulta en una reducción de la albuminuria y a una disminución de la hiperfiltración glomerular, lo cual conlleva a una mejor conservación de la función renal a largo plazo 8 .…”